CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01533727
Recruitment Status : Withdrawn (Few patients would like to participate ,since CIK cell transfusion was a new treatment and its efficacy was doubted.)
First Posted : February 15, 2012
Last Update Posted : December 9, 2013
Information provided by (Responsible Party):
Li Zhang, Sun Yat-sen University

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : December 2017
  Estimated Study Completion Date : December 2020